Tuesday, May 5, 2026
Today's Print

Tag: Krishna Ella

Bharat Biotech’s Covaxin Phase 3 interim efficacy at 81%

The Phase 3 clinical trial results of Bharat Biotech's coronavirus vaccine candidate, Covaxin, yielded an 81 percent interim efficacy in India. "Covaxin demonstrated 81 percent...
- Advertisement -spot_img
- Advertisement -spot_img